CD47 and cancer: Furthermore, it has been shown that CD47/SIRPα and SIRPα signaling negatively regulate antibody-dependent elimination of tumor cells, which supports the idea of targeting CD47/SIRPα interaction to enhance the clinical effects of cancer therapeutic antibodies [40].